Under the joint venture agreement, Moderna (MRNA) will handle the manufacturing, sales, medical education and distribution of its mRNA respiratory vaccines.
Both companies will engage in activities to enable broad access to Moderna’s (MRNA) mRNA respiratory portfolio to have the maximum impact on public health in Japan, the American pharmaceutical said in a statement.
The agreement has an initial term until March 31, 2029, and no further details on the financial terms of the deal were disclosed.
“We are pleased to partner with Mitsubishi Tanabe Pharma to enable the commercialization of our COVID-19 vaccine and future mRNA respiratory vaccine portfolio to the people of Japan,” said Kazumasa Nagayama, President and Representative Director of Moderna (MRNA) Japan.
